

# 5-hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6-(3-methylbut-2-enyl)pyrano[2,3-h]chromen-4-one

Giovanni Ribaudò <sup>1,\*</sup>, Alberto Ongaro <sup>1</sup> and Giuseppe Zagotto <sup>1</sup>

<sup>1</sup> Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5 Padova, Italy

- SUPPLEMENTARY MATERIAL -

# <sup>1</sup>H NMR Spectra




Figure S1. <sup>1</sup>H (CDCl<sub>3</sub>, 400 MHz) spectrum of compound 2.




Figure S2. <sup>1</sup>H (CDCl<sub>3</sub>, 400 MHz) spectrum of compound 2 with peaks integration.

# <sup>13</sup>C NMR Spectra




Figure S3. <sup>13</sup>C (CDCl<sub>3</sub>, 100 MHz) spectrum of compound 2.

## NOESY




Figure S4. NOESY ( $\text{CDCl}_3$ , 400 MHz) spectrum of compound **2**.




Figure S5. NOESY ( $\text{CDCl}_3$ , 400 MHz) spectrum of compound **2**, detail of the 0-8 ppm region.




Figure S6. NOESY (CDCl<sub>3</sub>, 400 MHz) spectrum of compound **2**, detail of the 0-4 ppm region.

#### HSQC




Figure S7. HSQC (CDCl<sub>3</sub>, 400 MHz) spectrum of compound **2**.




Figure S8. HSQC detail (CDCl<sub>3</sub>, 400 MHz) spectrum of compound 2.




Figure S9. HSQC detail (CDCl<sub>3</sub>, 400 MHz) spectrum of compound 2.

# HMBC





Figure S10. HMBC (CDCl<sub>3</sub>, 400 MHz) spectrum of compound 2.


## MASS SPECTROMETRY



**Figure S11.** Mass spectrum of compound **2**. The spectrum was recorded in positive ionization mode (ESI).



## HPLC AND UV CHARACTERIZATION



Signal 1: DAD1 A, Sig=254,4 Ref=off

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	2.176	BB	0.1771	23.89660	1.68867	1.2188
2	2.833	BB	0.1951	14.01157	1.01455	0.7147
3	16.099	BB	0.0702	7.67188	1.59288	0.3913
4	16.801	BV	0.2465	32.24067	1.64595	1.6444
5	18.398	BB	0.1316	62.62463	6.21021	3.1941
6	19.191	BB	0.1365	1820.16760	176.26939	92.8367

Totals : 1960.61296 188.42165

Figure S12. HPLC chromatogram and peaks table of compound 2.





Figure S13. UV spectrum of compound 2.

## DOCKING STUDIES



**Figure S14.** 3D interaction poses of sildenafil (blue) and **2** (orange) docked to PDE5 (PDB ID: 2H42): (a) Compound **2** preferentially binds the catalytic site of PDE5 where sildenafil exploits its action; (b) Comparison between the poses of sildenafil and **2**; (c) Detailed representation of the molecular interactions between the compounds and the residues of the catalytic site of PDE5. H-bond between Ser663 and **2** is highlighted in red.

**Table S1.** Estimated  $\Delta G$  (kcal/mol) values for the computed interactions for the compounds and interacting residues with PDE5 (PDB ID: 2H42).

<b>Compound</b>	<b>Estimated <math>\Delta G</math> (kcal/mol)</b>	<b>Interacting residues of PDE5</b>
osajin ( <b>1</b> )	-8.4	Tyr612, His613, His617, Ile665, Asp764, Leu804, Met816, Gln817, Phe820
<b>2</b>	-10.7	Leu604, Ser663, Ile665, Leu725, Val782, Phe786, Phe820
sildenafil	-9.7	Leu604, Ile665, Leu725, Val782, Phe786, Phe820